structur growth intact
make minor forecast earn chang ebit maintain target
price outperform rate weak middl eastern market
impact group organ growth nvz realiz continu
drag weak push acceler organ growth
howev continu forecast return mid-high singl digit structur growth
support hygien launch corn inocul uptak share gain
energy/household oil price remain elev estim
oil novozym grow core busi
growth new product pipelin believ market gain
comfort return higher growth share continu outperform
european chemic increasingli uncertain
middl east hold back household declin middl eastern
market iran saudi turkey egypt impact group organ growth
disproportion weight toward household estimate
divis exclud cyclic weak divis would grown organ
sale indic take new hygien product
progress well cs estimate contribut expans emerg market
continu whilst visibl low cyclic weak market
gain comfort underli penetr novozym product
increas forecast return growth driven hygien
roll asia/europ share gain /asia penetr
valuat risk valu novozym averag
price-to-earnings multipl ev/ebitda multipl
dcf wacc estim novozym
structur increas growth rate prove resili
european chemic econom downturn scenario given defens
end market new market penetr opportun risk
invest case lower oil price impact market share assumpt
valuat metric
price month
price rel chart measur perform
omxc close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
novozym a/ denmark-bas biotechnolog compani
engag product sale industri enzym
busi consist two segment enzym busi segment
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
return peak oil would gener organ growth
could justifi novozym rerat toward histor pe premium
return trough oil would gener organ growth could
justifi novozym derat toward low end histor pe
trade
price rel chart measur perform omxc
close
spot exchang rate
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
downgrad forecast ebit forecast period organ growth
averag function
household reduc organ growth given on-going
headwind cyclic weak middl east continu believ
roll hygien penetr asia share gain chemic enzym
switch higher oil return busi organ growth
temper growth rate given uncertainti market
ag feed make minor adjust forecast organ growth ag feed
account time sale bioag
margin overal model underli bp margin improv per annum base
improv product product
figur credit suiss earn forecast chang novozym
highlight month forward consensu ev/ebitda novozym trade
discount peer discount year averag vs peer
month forward consensu price-to-earnings novozym trade discount peer
discount year histor averag vs peer
rel
compani mention price
